PMID: 6401951Jan 1, 1983Paper

Transdermal absorption of nitroglycerin from microseal drug delivery (MDD) system

Angiology
A Karim

Abstract

A recent important advance in biopharmaceutics has been the utilization of controlled delivery of drugs to the systemic circulation through the intact skin. With the conventional tablet and capsule dosage forms, the amount of drug absorbed through the gastrointestinal (GI) tract varies depending on the quantity and types of food in the stomach, on the GI motility and transit time. Acid and/or alkaline labile drugs may be deactivated prior to absorption from the GI tract while some drugs also get deactivated by GI microbial flora. In the case of drugs with a high hepatic extraction ratio, the absorbed drug may be largely deactivated by first-pass metabolism before reaching the systemic circulation. Drug absorption through the GI tract can therefore result in variable and/or unpredictable blood levels. Some of this variability can be minimized by administering controlled-release tablet or capsule formulations. However, these dosage forms cannot eliminate the inherent variability associated with first-pass metabolism.

References

Mar 1, 1979·Circulation·P W ArmstrongG S Marks
Sep 1, 1981·Journal of Pharmaceutical Sciences·E F McNiffH L Fung
Oct 1, 1980·The American Journal of Cardiology·P W ArmstrongG S Marks
Dec 1, 1981·Journal of Pharmaceutical Sciences·S SvedI J McGilveray

❮ Previous
Next ❯

Citations

Jan 15, 1999·Microsurgery·C Campisi, F Boccardo
Jan 1, 1985·European Journal of Clinical Pharmacology·P A Cossum, M S Roberts
Oct 1, 1984·Klinische Wochenschrift·H GrothW Vetter
Jan 1, 1992·European Journal of Clinical Pharmacology·T O KlemsdalJ E Bredesen
Nov 16, 1987·The American Journal of Cardiology·H L Fung
Feb 1, 1989·Journal of the American College of Cardiology·A E Moreyra, J B Kostis
May 1, 1985·Journal of the American College of Cardiology·M SullivanV Froelicher
Dec 1, 1989·Journal of Neurology, Neurosurgery, and Psychiatry·S BonusoE A Ullucci
Jan 1, 1990·Biomaterials, Artificial Cells, and Artificial Organs·R TekinE Pişkin
Jul 1, 1986·Journal of Pharmaceutical Sciences·P K NoonanA Cohen
Oct 1, 1984·Journal of Pharmaceutical Sciences·A YacobiG Nicolau
Feb 1, 1993·Journal of Pharmaceutical Sciences·J I AdemolaH I Maibach
Jan 1, 1989·Journal of the American Academy of Dermatology·B J BartJ L Neveaux
Jun 27, 1983·The American Journal of Medicine·H L Fung
Jul 1, 1986·American Heart Journal·B Charash, S S Scheidt
Dec 27, 1985·The American Journal of Cardiology·S Scheidt
Jul 10, 1985·The American Journal of Cardiology·J Abrams
Mar 15, 1989·The American Journal of Cardiology·E G NabelA P Selwyn
Jan 1, 1987·International Journal of Cardiology·U Thadani
Jul 1, 1985·Biopharmaceutics & Drug Disposition·S H Curry, S M Aburawi
Aug 1, 1985·The Journal of Pediatrics·N J EvansG Parr
Sep 1, 1984·The American Journal of Cardiology·J O Parker, H L Fung
Jun 22, 1984·The American Journal of Medicine·J Abrams
Nov 1, 1986·The American Journal of Medicine·G Moe, P W Armstrong
Jul 1, 1984·The American Journal of Cardiology·J Abrams
Oct 1, 1991·The American Journal of Cardiology·P A de MillianoA van de Bos
Jan 7, 2015·British Journal of Pharmacology·Michael N PastoreMichael S Roberts
Mar 1, 1987·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·R H GuyD A Bucks
Oct 1, 1986·Journal of Biomaterials Applications·M Szycher
Apr 1, 1987·Angiology·R K MahapatraS Yaden
Nov 1, 1987·Drug Intelligence & Clinical Pharmacy·F P Zeller

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.